Legend Biotech

We are a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases through cell therapy. Cell therapy is a process of using a patient’s own cells to better fight disease and disease progression. We are committed to helping patients around the world through our cell therapy discoveries.

If you’d like to work with passionate people who are helping to bring cutting-edge options to patients around the world, join us. We are always looking for people who can contribute to the strength of our team and build on our shared values. Our headquarters is located in Somerset, New Jersey, but we also have R&D facilities and manufacturing sites for scientific exploration, development and delivery: Piscataway, NJ; Dublin, Ireland; Ghent, Belgium; Nanjing, China.

In pursuit of cures.
Creating a future where cancers and intractable diseases are curable.
To become the global leader in cell and gene therapy.
We aspire to be the global leader in cell and gene therapy by creating transformative therapies that change treatment paradigms.

Patient First: Extending and improving patients’ lives is our top priority. The needs of patients guide every aspect of our business.

Innovation: Innovation is our compass. We encourage creativity and curiosity to drive scientific breakthrough, we take strategic risks and push boundaries in our relentless pursuit of cures.

One Team: One team, one purpose. We collaborate across regions and functions, embrace diversity, communicate openly and build a culture of trust.

Result Driven: We are proactive and focused on delivering positive outcomes. We don’t give up and make things happen.

Integrity: We conduct our business honestly, ethically and transparently both internally and externally.

NEWS
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
FDA
The approvals, third line for BMS and 2seventy Bio’s Abecma and second line for J&J and Legend Biotech’s Carvykti, represent a new class of therapy for these blood cancer patients.
April kicks off with three FDA target action dates, including one that could potentially set the stage to move CAR-T therapies into earlier lines of treatment.
By votes of 11-0 and 8-3, respectively, an FDA advisory committee Friday deemed the risks of early death for both Johnson & Johnson’s Carvykti and Bristol Myers Squibb’s Abecma acceptable.
The FDA’s busy week ahead involves three decision dates for potential industry firsts and a highly anticipated advisory committee meeting for two CAR-T therapies.
Johnson & Johnson and Legend Biotech got a positive opinion from a European Medicines Agency panel for earlier lines of treatment, as they ready for a March FDA advisory committee meeting.
An FDA advisory committee will meet to review J&J and Legend Biotech’s supplemental BLA for Carvykti for the treatment of relapsed or refractory multiple myeloma patients who have undergone at least one prior line of therapy.
As CAR T cell therapies attract significant biopharma investment, experts say there is plenty of space in the growing market for both treatments that use patients’ own cells and for those that rely on donor cells.
After success with J&J, Legend strikes another license agreement, this one with Swiss pharma Novartis around CAR-T therapies.
JOBS
IN THE PRESS